As expected, the median proportion of CD30+ HRS cells from the whole tumor cellularity was low (median 1.8%, range 0.06–20%), and about half of CD30+ HRS cells were PD-L1+ (median 47%, range 0–92%) (Figure 1c). The gene discussed is TNFRSF8; the disease is neoplasm.